Liquid biopsies have emerged as a groundbreaking approach in cancer diagnostics, enabling the detection of DNA shed by cancer cells through a simple blood test. However, cancer cells also shed RNA into the blood.
Stanford researchers have identified that increased oxidative stress is a key molecular signature of fatigue-based conditions including Long COVID and myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS).
Stanford scientists develop a method for assessing patient risk of developing postsurgical neurocognitive complications using a combination of biomarkers. This method will ensure improved interventions and treatment outcomes.
The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford BIODESIGN researchers have developed a disease breathalyzer for detecting necrotizing enterocolitis in newborns. Newborn babies face a high risk of blood infections (sepsis) and gastrointestinal inflammation and injury disease (necrotizing enterocolitis 'NEC').
Stanford researchers have formulated a first in line framework called EcoTyper which systematically profiles the tumor microenvironment (TME) cell states in multiple solid tumor types, providing a platform for effective personalized cancer decisions.
Researchers at Stanford have developed a nucleic acid amplification test to detect high-risk Epstein-Barr Virus (EBV) BALF2 variants in plasma to aid population-level screening for nasopharyngeal carcinoma (NPC).
Stanford Medicine's Ji Research Group has developed a simple, quantitative method for detecting and characterizing gene fusions that uses DNA rather than RNA as analyte.
Stanford scientists have created a de novo protein design platform that designs binding proteins that specifically target antigens in the major histocompatibility complex (MHC).
Stanford and Northwestern scientists have discovered that Platelet Factor 4 (PF4) is a biomarker for lymphatic diseases, such as lipedema and lymphedema, and can reliably differentiate them from obesity, which is a common misdiagnosis.
There is an urgent need for the development of sensitive, specific and non-invasive biomarkers for the diagnosis and management of patients with enteropathic diseases such as celiac sprue.
Stanford scientists have discovered that differentially methylated regions (DMRs) in circulating tumor DNA (ctDNA) can be used as a blood-based biomarker for early cancer detection.
Stanford University researchers have developed aptamer-antibody chimeras that achieve dynamic, sensitive, and specific biomolecule sensing beyond the capacity of antibodies or aptamers alone.